NASDAQ:GNTA 24 October 2025

Genenta Science Stock Skyrockets on Strategic Gene-Therapy Alliance – Is a $25 Price Target Next?

Genenta Science shares surged over 300% in early trading Oct. 24 after announcing an expanded partnership with Anemocyte to develop off-the-shelf lentiviral vector plasmid DNA for cell therapies. The company’s lead candidate Temferon showed a 29% two-year survival rate in glioblastoma patients, more than double standard care. Net loss narrowed to €3.83M in H1 2025. Analyst targets average $22.73, far above current prices.

24 October 2025

Biotechnology·NASDAQ:GNTA·Stock Market

Nevada Temporarily Bans Prediction Market Firm Kalshi Over Gaming License Dispute
March 20, 2026, 2:30 PM EDT. Kalshi, a prediction markets platform offering event-based contracts on sports, elections, and entertainment, was temporarily banned in Nevada by a 14-day restraining order from the First Judicial District Court. The ruling prohibits Kalshi from operating its derivatives exchange without a gaming license, marking the first state-level forced cessation for the company. The ban follows earlier Nevada cease-and-desist actions and precedes a likely extension through the legal case, said gaming attorney Daniel Wallach. The dispute comes amid mounting regulatory scrutiny nationally, including criminal charges from Arizona and ongoing battles in multiple states. Kalshi contends its sports contracts are financial swaps, not gambling, a view supported by the federal Commodity Futures Trading Commission, which claims jurisdiction over these markets. This case highlights tensions between state gambling laws and federally regulated prediction markets.